Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Spectrum's Poziotinib Failed to Meet Primary Phase II Trial Endpoint

Spectrum's Poziotinib Failed to Meet Primary Phase II Trial Endpoint

Dec 27, 2019
|
staff reporter

NEW YORK – Spectrum Pharmaceuticals said Thursday that its drug candidate poziotinib failed to meet the pre-specified primary endpoint in the first cohort of participants in a Phase II clinical trial investigating patients with pret

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

What's Popular?

In Drug Discovery & Development

  1. Kronos Bio to Proceed With Phase III Trial of Entospletinib in NPM1-Mutated AML

  2. After Setbacks, Innate Pharma on Track to Advance NK Cell-based Immunotherapy Pipeline

    Premium

  3. Epizyme Exploring Tazverik Combinations in Basket Trials

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.